Recent performance snapshot and business context

Oculis Holding (NasdaqGM:OCS) has attracted fresh attention after recent trading, with the stock last closing at $29.49. Investors are weighing this price against the company’s clinical-stage pipeline and current financial profile.

At $29.49, the stock has pulled back around 4.9% over the last day but still sits on a year-to-date share price return of about 47%, alongside a 1-year total shareholder return of roughly 55%, which points to firm but recently tested momentum.

If you are looking beyond a single clinical-stage biotech and want more ideas in a similar space, this is a good moment to scan 34 healthcare AI stocks

With Oculis Holding showing a 47% year to date gain and trading at $29.49, the key question is whether its clinical pipeline and current losses are fairly reflected in the price, or if the stock still represents a potential buying opportunity that markets have not fully priced in.

Preferred price to book of 7x: Is it justified?

On a P/B of 7x at a last close of $29.49, Oculis Holding trades well above both its peer group and the wider US pharmaceuticals sector. This points to a rich valuation based on this metric.

The P/B ratio compares the company’s market value to its book value, so a higher figure usually means investors are paying more for each dollar of net assets. For a clinical stage biopharmaceutical company that is still loss making, this kind of premium often reflects expectations around the potential of the pipeline rather than current earnings power.

Here, Oculis Holding looks expensive on two fronts, with its 7x P/B above the peer average of 6.1x and also above the broader US pharmaceuticals industry average of 2.3x. That is a clear signal that the market is assigning a higher value to its balance sheet and prospects than to many competitors. This raises the bar for future execution if this valuation premium is to be maintained.

Result: Preferred multiple of price to book of 7x (OVERVALUED)

However, the stock’s premium P/B and current net loss of $94.596 million mean that any clinical setback or funding pressure could quickly challenge today’s valuation.

Another view using our DCF model

The high 7x P/B ratio suggests Oculis Holding is expensive, but the SWS DCF model tells a very different story. With the stock at $29.49 versus an estimated future cash flow value of $186.84, it appears to be trading about 84.2% below that fair value estimate.

This kind of gap can highlight either a mispricing that might close over time or risks in the underlying assumptions that the market is not prepared to embrace. Which side of that debate do you think is closer to the truth for Oculis Holding?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Oculis Holding for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 48 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Balancing clear risks with potential rewards can make this story feel finely poised, so it is worth checking the numbers yourself and deciding where you stand. To see both sides clearly, review the 2 key rewards and 3 important warning signs

Looking for more investment ideas?

If you stop with just one stock, you risk missing out on other opportunities that may fit your goals even better. Take a few minutes to scan wider.

• Spot potential bargains with strong fundamentals by checking out 48 high quality undervalued stocks.
• Prioritise resilience and capital preservation by reviewing 69 resilient stocks with low risk scores.
• Hunt for promising companies that are still under the radar through screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.